

Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/363,748</b>	Group Art Unit <b>1 6 2 3</b>	Attachment to Paper Number	<b>3 5</b>
Notice of References Cited	APPLICANT(S) <b>Watkins et al.</b>			

### Published U. S. Patent Applications

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
	<b>P 1</b>	<b>2003/0114415 A1</b>	<b>06/19/03</b>	<b>Wurtman et al.</b>	<b>5 1 4</b>	<b>051.000</b>	

### U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	<b>A</b>	<b>5,583,117 A</b>	<b>12/10/96</b>	<b>von Borstel et al. (I)</b>	<b>5 1 4</b>	<b>050.000</b>	
*	<b>B</b>	<b>5,962,459 A</b>	<b>10/06/00</b>	<b>Piazza et al.</b>	<b>5 1 4</b>	<b>269.000</b>	
	<b>C</b>	<b>6,472,378 B2</b>	<b>10/29/02</b>	<b>von Borstel et al. (II)</b>	<b>5 1 4</b>	<b>050.000</b>	

### Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
*	<b>L</b>	<b>EP 0,178,267 A2</b>	<b>04/16/86</b>	<b>Europe(EPO)</b>	<b>Polifarma SpA</b>	<b>-----</b>	<b>-----</b>		
*	<b>M</b>	<b>W O 89/03837 A1</b>	<b>05/05/89</b>	<b>World(PCT/WO)</b>	<b>Proneuron, Inc.</b>	<b>-----</b>	<b>-----</b>		
*	<b>N</b>	<b>W O 97/43899 A1</b>	<b>11/27/97</b>	<b>World(PCT/WO)</b>	<b>Breonics, Inc.</b>	<b>-----</b>	<b>-----</b>		
*	<b>O</b>	<b>W O 97/45127 A1</b>	<b>12/04/97</b>	<b>World(PCT/WO)</b>	<b>Poliframa, SpA</b>	<b>-----</b>	<b>-----</b>		
*	<b>P††</b>	<b>JP07/215,879 A</b>	<b>08/15/95</b>	<b>Japan(JPO)</b>	<b>Otsuka Seiyaku</b>	<b>-----</b>	<b>-----</b>		
	<b>Q††</b>	<b>JP09/30976 A2</b>	<b>02/04/97</b>	<b>Japan(JPO)</b>	<b>Otsuka Pharma Co.</b>	<b>-----</b>	<b>-----</b>		
	<b>LA††</b>	<b>JP2001/233776 A2</b>	<b>08/28/01</b>	<b>Japan(JPO)</b>	<b>Yamasa Shoyu Co.</b>	<b>-----</b>	<b>-----</b>		
	<b>MA</b>	<b>W O 00/50043 A1</b>	<b>08/31/00</b>	<b>World(PCT/WO)</b>	<b>Regents Univ. Calif.</b>	<b>-----</b>	<b>-----</b>		

†† English Abstract included.


EXAMINER <b>L. E. Crane</b>	DATE <b>11/06/03</b>	<b>page 1 of 4</b>
¥: Reference not presently available.		
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/363,748</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number	<b>35</b>
Notice of References Cited	APPLICANT(S)			
	Watkins et al.			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

* R	Page et al., "Developmental Disorder Associated with Increased Cellular Nucleotidase Activity," <i>Proc. National Academy of Sciences USA</i> , 94(21), 11601-11606 (Oct. 14, 1997).
S	Coirault et al., "Uridine 5-Triphosphate in Therapy. I. Cure of Neurogenic Muscular Atrophy," <i>La Presse Medicale(Fr.)</i> , 68(29), 1127-1129 (June 11, 1960); <i>Chemical Abstracts</i> , 57(7), p. 73, Abstract No. 10485f (October 1, 1962).
T	Merlini et al., "Effects of Large Doses of Pyrimidine Nucleosides Cytidine and Uridine in Elderly Patients with Neuropsychological Disturbances Caused by Vascular and Cerebral Metabolic Insufficiency," <i>Gazzetta Medica Italiana Archivio Scienze Mediche</i> , 145(6), 379-390 (June, 1966); <i>Biological Abstracts</i> , 83, Abstract No. 27367 (1987).
U†	Gallai et al. (I), "Effects of Uridine in the Treatment of Diabetic Neuropathy: An Electrophysiological Study," <i>Acta Neurol. Scand.</i> , 86(1), 3-7 (1992); <i>Biological Abstracts</i> , 94, Abstract No. 112030 (1992).
V†	Gallai et al. (II), "Multi-Infarct Dementia: Modification of the P300 Cognitive Event-Related Potential in Patients Treated with the Association of Cytidine and Uridine," <i>Rivista di Neuropsichiatria e Scienze Affini</i> , 41(1), 1-9 (1995); <i>BIOSIS</i> , 1996, Abstract Citation Number 466219; only Abstract supplied.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER L. E. Crane 	DATE <b>11/06/03</b>	<b>page 2 of 4</b> ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/363,748</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number	<b>35</b>
Notice of References Cited		APPLICANT(S) <b>Watkins et al.</b>		

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

<b>W†</b>	<b>Drago et al.</b> , "Memory Deficits of Aged Male Rats Can Be Improved by Pyrimidine Nucleosides and N-Acetylglutamine," <i>Clinical Neuropharmacology</i> , 13(4), 290-296 (1990); <i>Biological Abstracts</i> , 90, Abstract No. 91117 (1990).
<b>X†</b>	<b>Manna et al.</b> , "Effects of Short-Term Administration of Cytidine, Uridine and L-Glutamine Alone or in Combination on the Cerebral Electrical Activity of Patients with Chronic Cerebrovascular Disease," <i>Intl. Journal Clinical Pharmacology Research</i> , 8(3), 199-210 (1988); <i>Biological Abstracts</i> , 86, Abstract No. 51989 (1988).
<b>Y</b>	<b>Keilbaugh et al.</b> , "Anti-Human Immunodeficiency Virus Type 1 Therapy and Peripheral Neuropathy: Prevention of 2', 3'-Dideoxycytidine Toxicity in PC12 Cells, a Neuronal Model, by Uridine and Pyruvate," <i>Molecular Pharmacology</i> , 44(4), 702-706 (October 1, 1993); <i>BIOSIS</i> , 1994, Abstract Citation Number 413648.
<b>Z†</b>	<b>Popov et al.</b> , "Protective Effect of Uridine on D-Galactosamine-Induced Deficiency in Brain Uridine Phosphates," <i>Biomedica Biochimica Acta</i> , 43(12), 1399-1404 (1984); <i>Biological Abstracts</i> , 80, Abstract No. 34525 (1985).
<b>* RA†</b>	<b>Ingraham et al.</b> , "Nucleoside Diphosphokinase from <i>Salmonella typhimurium</i> ," Chapter 48 in <u>Methods in Enzymology</u> , LI(vol. 51), Hoffee et al. (eds.), New York, NY, 1978, Academic Press, only pages 371 and 375 supplied; assorted portions of other chapters were also supplied including pages 305, 306, 318, 327, 329 and 330.††

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane 	DATE <b>11/06/03</b>	<b>page 3 of 4</b> ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		


Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/363,748</b>	Group Art Unit <b>1 6 2 3</b>	Attachment to Paper Number	<b>3 5</b>
Notice of References Cited	APPLICANT(S) <b>Watkins et al.</b>			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

SA	Miyazaki et al., "Effects of Nucleotides on Learning and Memory in a Morris Water Maze Test in Normal and Basal Forebrain-Lesioned Rats," <i>Life Sciences</i> , 64(1), 45-52 (November 27, 1998).
TA	Entingh et al., "Brain Uridine Monophosphate: Reduced Incorporation of Uridine During Avoidance Learning," <i>Brain Research</i> , 70(1), 131-138 (April 12, 1974); only abstract supplied.
UA	Rüthrich et al., "Increase of Guanosine Incorporation into RNA of Hippocampal Neurons by Application of Uridine Monophosphate During a Learning Experiments," <i>Brain Research</i> , 69(1), 49-55 (March 29, 1974); only abstract supplied.
VA	Ott et al. (I), "Effects of RNA Precursors on Development and Maintenance of Long-Term Memory," <i>Psychopharmacologia</i> , 28(2), 195-204 (1973); <i>Chemical Abstracts</i> , 78(19), p. 77, Abstr. No. 119731q, (May 14, 1973); only Abstract supplied.
WA	Ott et al. (II), "Influence of 6-Azauridine on Facilitation of Relearning by Precursors of Ribonucleic Acid," <i>Psychopharmacologia</i> , 23(3), 272-278 (1972); <i>Chemical Abstracts</i> , 76(25), p. 103, Abstract No. 149588z, (June 19, 1972); only Abstract Supplied.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy supplied by applicant.

EXAMINER L. E. Crane 	DATE <b>11/06/03</b>	<b>page 4 of 4</b> ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		